Population-based incidence, clinical phenotypes and toxicity-related mortality of immune-related myositis, myocarditis and myasthenia-like overlap (ir-MMM): study

Background Immune checkpoint inhibitors (ICIs) often induce immune-related adverse events (irAEs). A potentially fatal irAE is immune-related (ir) myositis and ir-myocarditis, particularly the ir-myositis-myocarditis-myasthenia overlap (ir-MMM). Evidence derives from trials, pharmacovigilance and specialist-centre series, leaving population-based incidence and phenotype-specific risk poorly defined. Patients and methods In a retrospective, population-based cohort, we included all adult patients with cancer treated with ICIs (anti-programmed cell death protein 1/anti-programmed death-ligand 1 and/or anti-cytotoxic T-lymphocyte-associated protein 4) in the Region of Southern Denmark from September 2013 to December 2024. Natural language processing of electronic health records and laboratory data identified potential cases, which were confirmed by expert adjudication. Patients were classified as having isolated ir-myositis, isolated ir-myocarditis or ir-myositis-myocarditis overlap; bulbar/ocular involvement defined ir-MMM. Primary outcomes were phenotype distribution and toxicity-related mortality. Results Among 2893 ICI-treated patients, 53 (1.8%) developed ir-myositis and/or ir-myocarditis: isolated ir-myositis in 13 of 53 (24%), isolated ir-myocarditis in 12 of 53 (23%), and overlap in 28 of 53 (53%), including 15 (28%) with ir-MMM. Five (9%) died of toxicity, all in the overlap group, and four of five (80%) had ir-MMM. Dyspnoea and bulbar/ocular symptoms were present in 100% and 80% of fatal cases. Median peak high-sensitivity cardiac troponin T (hs-cTnT) was nearly 10-fold higher in fatal (2540 ng/l) than in nonfatal cases (274 ng/l). Isolated ir-myositis caused no deaths but was long-lasting (92% experienced for >6 months). Conclusions Ir-myositis and/or ir-myocarditis occurred in ∼2% of ICI-treated patients. Mortality was confined to overlap, particularly ir-MMM, and was associated with dyspnoea, bulbar/ocular symptoms and markedly elevated hs-cTnT concentration, features not captured by Common Terminology Criteria for Adverse Events (CTCAE) grading. Our findings support phenotype-based risk stratification over CTCAE grading.

Authors

Institutions

Publication Details

Journal
ESMO Real World Data and Digital Oncology
Published
2026-11-18
DOI
https://doi.org/10.1016/j.esmorw.2026.101197
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Population-based incidence, clinical phenotypes and toxicity-related mortality of immune-related myositis, myocarditis and myasthenia-like overlap (ir-MMM): study

Hanne Lindegaard, Søren Andreas Just, Janine Sophie Kemming, Christina H. Bruvik Ruhlmann et al.
1 links
ESMO Real World Data and Digital Oncology
Cancer Immunotherapy and Biomarkers
article

Population-based incidence, clinical phenotypes and toxicity-related mortality of immune-related myositis, myocarditis and myasthenia-like overlap (ir-MMM): study

Hanne Lindegaard, Søren Andreas Just, Janine Sophie Kemming, Christina H. Bruvik Ruhlmann, Ann Banke, Helene Broch Tenstad, S.R. Hadrup, P.J. Vinholt, M. Schäfer, R.B. Lynggaard, M. Ejby
article en

Abstract

Background Immune checkpoint inhibitors (ICIs) often induce immune-related adverse events (irAEs). A potentially fatal irAE is immune-related (ir) myositis and ir-myocarditis, particularly the ir-myositis-myocarditis-myasthenia overlap (ir-MMM). Evidence derives from trials, pharmacovigilance and specialist-centre series, leaving population-based incidence and phenotype-specific risk poorly defined. Patients and methods In a retrospective, population-based cohort, we included all adult patients with cancer treated with ICIs (anti-programmed cell death protein 1/anti-programmed death-ligand 1 and/or anti-cytotoxic T-lymphocyte-associated protein 4) in the Region of Southern Denmark from September 2013 to December 2024. Natural language processing of electronic health records and laboratory data identified potential cases, which were confirmed by expert adjudication. Patients were classified as having isolated ir-myositis, isolated ir-myocarditis or ir-myositis-myocarditis overlap; bulbar/ocular involvement defined ir-MMM. Primary outcomes were phenotype distribution and toxicity-related mortality. Results Among 2893 ICI-treated patients, 53 (1.8%) developed ir-myositis and/or ir-myocarditis: isolated ir-myositis in 13 of 53 (24%), isolated ir-myocarditis in 12 of 53 (23%), and overlap in 28 of 53 (53%), including 15 (28%) with ir-MMM. Five (9%) died of toxicity, all in the overlap group, and four of five (80%) had ir-MMM. Dyspnoea and bulbar/ocular symptoms were present in 100% and 80% of fatal cases. Median peak high-sensitivity cardiac troponin T (hs-cTnT) was nearly 10-fold higher in fatal (2540 ng/l) than in nonfatal cases (274 ng/l). Isolated ir-myositis caused no deaths but was long-lasting (92% experienced for >6 months). Conclusions Ir-myositis and/or ir-myocarditis occurred in ∼2% of ICI-treated patients. Mortality was confined to overlap, particularly ir-MMM, and was associated with dyspnoea, bulbar/ocular symptoms and markedly elevated hs-cTnT concentration, features not captured by Common Terminology Criteria for Adverse Events (CTCAE) grading. Our findings support phenotype-based risk stratification over CTCAE grading.

ESMO Real World Data and Digital OncologyVol. 14
University of Southern Denmark (DK), Odense University Hospital (DK), Svendborg Sygehus (DK), Technical University of Denmark (DK)
Region Syddanmark, Danmarks Frie Forskningsfond, Gangstedfonden
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon